WallStreetZenWallStreetZen

NASDAQ: ESPR
Esperion Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ESPR

Based on 4 analysts offering 12 month price targets for Esperion Therapeutics Inc

Min Forecast
$3.00+38.25%
Avg Forecast
$6.75+211.06%
Max Forecast
$16.00+637.33%

Should I buy or sell ESPR stock?

Based on 4 analysts offering ratings for Esperion Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 75%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ESPR's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ESPR as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ESPR stock forecasts and price targets.

ESPR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-17
lockedlocked$00.00+00.00%2025-05-07
lockedlocked$00.00+00.00%2025-04-17
lockedlocked$00.00+00.00%2025-03-05

1 of 1

Forecast return on equity

Is ESPR forecast to generate an efficient return?

Company
-39.53%
Industry
30.84%
Market
-49.12%
ESPR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ESPR forecast to generate an efficient return on assets?

Company
49.38%
Industry
14.66%
ESPR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ESPR earnings per share forecast

What is ESPR's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.06
Avg 2 year Forecast
$0.01
Avg 3 year Forecast
$0.26

ESPR revenue forecast

What is ESPR's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$361.4M+34.78%
Avg 2 year Forecast
$360.1M+34.3%
Avg 3 year Forecast
$404.1M+50.71%
ESPR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ESPR revenue growth forecast

How is ESPR forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
13.74%
Industry
4.22%
Market
10.83%
ESPR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ESPR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ESPR vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
ESPR$2.17$6.75+211.06%Buy
KMDA$7.18$13.00+81.06%Strong Buy
ETON$17.30$29.67+71.49%Strong Buy
AQST$3.98$8.33+109.37%Strong Buy
EOLS$7.68$21.25+176.69%Strong Buy
View Top Pharmaceutical Stocks

Esperion Therapeutics Stock Forecast FAQ

Is Esperion Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: ESPR) stock is to Buy ESPR stock.

Out of 4 analysts, 0 (0%) are recommending ESPR as a Strong Buy, 3 (75%) are recommending ESPR as a Buy, 1 (25%) are recommending ESPR as a Hold, 0 (0%) are recommending ESPR as a Sell, and 0 (0%) are recommending ESPR as a Strong Sell.

If you're new to stock investing, here's how to buy Esperion Therapeutics stock.

What is ESPR's earnings growth forecast for 2025-2027?

(NASDAQ: ESPR) Esperion Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 23.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.31%.

Esperion Therapeutics's earnings in 2025 is -$104,022,000.On average, 6 Wall Street analysts forecast ESPR's earnings for 2025 to be -$12,097,370, with the lowest ESPR earnings forecast at -$96,778,956, and the highest ESPR earnings forecast at $42,340,793. On average, 6 Wall Street analysts forecast ESPR's earnings for 2026 to be $1,673,469, with the lowest ESPR earnings forecast at -$44,357,022, and the highest ESPR earnings forecast at $70,567,989.

In 2027, ESPR is forecast to generate $53,087,290 in earnings, with the lowest earnings forecast at $10,081,141 and the highest earnings forecast at $118,957,467.

What is ESPR's revenue growth forecast for 2025-2027?

(NASDAQ: ESPR) Esperion Therapeutics's forecast annual revenue growth rate of 13.74% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.

Esperion Therapeutics's revenue in 2025 is $268,125,000.On average, 4 Wall Street analysts forecast ESPR's revenue for 2025 to be $72,864,472,727, with the lowest ESPR revenue forecast at $59,299,289,061, and the highest ESPR revenue forecast at $84,278,340,850. On average, 4 Wall Street analysts forecast ESPR's revenue for 2026 to be $72,602,766,300, with the lowest ESPR revenue forecast at $61,115,910,714, and the highest ESPR revenue forecast at $83,310,551,290.

In 2027, ESPR is forecast to generate $81,473,767,354 in revenue, with the lowest revenue forecast at $74,558,104,457 and the highest revenue forecast at $91,940,008,200.

What is ESPR's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ESPR) forecast ROA is 49.38%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 14.66%.

What is ESPR's Price Target?

According to 4 Wall Street analysts that have issued a 1 year ESPR price target, the average ESPR price target is $6.75, with the highest ESPR stock price forecast at $16.00 and the lowest ESPR stock price forecast at $3.00.

On average, Wall Street analysts predict that Esperion Therapeutics's share price could reach $6.75 by Jun 17, 2026. The average Esperion Therapeutics stock price prediction forecasts a potential upside of 211.06% from the current ESPR share price of $2.17.

What is ESPR's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ESPR) Esperion Therapeutics's current Earnings Per Share (EPS) is -$0.53. On average, analysts forecast that ESPR's EPS will be -$0.06 for 2025, with the lowest EPS forecast at -$0.48, and the highest EPS forecast at $0.21. On average, analysts forecast that ESPR's EPS will be $0.01 for 2026, with the lowest EPS forecast at -$0.22, and the highest EPS forecast at $0.35. In 2027, ESPR's EPS is forecast to hit $0.26 (min: $0.05, max: $0.59).

What is ESPR's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ESPR) forecast ROE is -39.53%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.